Summit Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Summit Therapeutics

02/08/2024 16:47

* Summit Therapeutics Inc  SMMT.OQ   SMMT.O  is expected
to report
resultson August 6 for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Summit Therapeutics Inc
is for
a loss of 6 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Summit
Therapeutics Inc is $13.50​, above​ its last closing price
of $10.66. ​​​

This summary was machine generated August 2 at 15:47 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)